In 2023, the turnover of basic pharmaceutical products in Switzerland stood at [value]. The forecasted data indicates a steady growth trajectory from 2024 to 2028, with turnover expected to rise from 29.15 billion euros in 2024 to 35.2 billion euros in 2028. Year-on-year growth percentages illustrate a consistent increase, averaging around 5% annually over the five-year period.
Future trends to watch for include technological advancements in pharmaceutical manufacturing, increased healthcare spending, and potential regulatory changes within the European Union that could impact Swiss pharmaceutical exports. Additionally, the rise of personalized medicine and biopharmaceuticals may further influence the market dynamics and drive future growth.
